References
- Abeles RH, Maycock AL. Suicide enzyme inactivators. Acct Chem Res 1976; 9: 313–319.
- Aswapokee N, Neu HC. A sulfone, beta-lactam compound which acts as a beta-lactamase inhibitor. J Antibiot 1978; 31: 1238–1243.
- Jones RN. In vitro evaluation of aminopenicillin-betalactamase inhibitor combinations. Drugs 1988; 36 (suppl. 7): 17–26.
- Ishida N, Higashitani F, Hanehara C, Uji T, Inque M, Mitsuhashi S. In vitro evaluation of new beta-lactamase inhibitor: YTR 830H and derivatives. J Chemother 1989; 1 (suppl. 4): 88–89.
- Chin NX, Neu HC. In vitro activity of YTR-830H in combination with beta-lactamase unstable beta-lactams. J Chemother 1989; 1 (suppl. 4): 90–92.
- Kuck NA, Petersen PJ, Weiss WJ, Jacobus NV, Testa RT, Tally FP. Synergistic activity of piperacillin: YTR-830H combinations in vitro and in vivo. J Chemother 1989; 1 (suppl. 4): 105–106.
- Lennette EH, Balows A, Hansler W Jr, Truant JP. Manual of Clinical Microbiology 4th ed. Washington DC: American Society for Microbiology, 1985.
- Jorgensen JM, Redding JS, Maher LH, Howell AW Improved medium for antimicrobial susceptibility testing of Haemophilus influenzae. J Clin Microbiol 1987; 25: 2105–2113.
- Jacobs MR, Aronoff SC, Johenning S, Yamaze S. Comparative activities of the beta-lactamase inhibitor YTR 830, clavulanate sulbactam combined with extended spectrum penicillins against ticarcillin-resistant Enterobacteriacee and Pseudomonads. J Antimicrob Chemother 1986; 18: 177–184.
- New HC. The role of beta-lactamase inhibitors in chemotherapy. Pharmac Ther 1985; 30: 1–18.
- Boyce JM, Medeiros AA. Role of beta-lactamase in expression of resistance by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1987; 31: 1426–1428.